H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Nurix Therapeutics to $19 from $35 and keeps a Buy rating on the shares. The analyst dropped the price target after taking into account the competitive landscape for BTK degraders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRIX:
- 3 Best Stocks to Buy Now, 2/19/2024, According to Top Analysts
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
- Nurix Therapeutics reports Q4 EPS (77c), consensus (57c)
- NRIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
